Cancers, Vol. 13, Pages 3887: Survival of Patients with Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small Cell Lung Cancer Treated beyond the Second Line in the Tyrosine Kinase Inhibitor Era

Conclusions: For patients receiving CT in second-line, TKI appears to be a better alternative in third-line compared to CT. Osimertinib may be used in third line treatment if not used before.

Source: Cancers - August 2, 2021 Category: Cancer & Oncology Authors: Val éry Refeno Michele Lamuraglia Safae Terrisse Cl ément Bonnet Cl ément Dumont Ludovic Doucet Damien Pouessel Stephane Culine Tags: Article Source Type: research